Jennifer Marvin-Peek, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses practical considerations for treating patients with IDH-mutated acute myeloid leukemia. Dr Marvin-Peek highlights the importance of managing toxicities and adjusting therapy duration based on patient tolerability.
Andrius Žučenka, MD, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania, discusses the challenges and advancements in treating acute myeloid leukemia (AML) in patients who are unfit for intensive…
Ruben A. Mesa, MD, director of the Mays Cancer Center at UT Health San Antonio MD Anderson Cancer Center, discusses barriers to achieving racially diverse clinical trials for…
Naval G. Daver, MD, a professor and director of the Leukemia Research Alliance Program, MD Anderson Cancer Center, Houston, Texas, highlighted significant advancements in acute myeloid leukemia (AML)…
Researchers from UC Davis Comprehensive Cancer Center discuss results from their recent study on long term complications adolescents and young adults face after treatment for acute myeloid leukemia…
Courtney DiNardo, MD, MSCE, clinical researcher in the Department of Leukemia of the Division of Cancer Medicine at the University of Texas MD Anderson Cancer Center, presents promising…
Courtney D. DiNardo, MD, clinical researcher in the Department of Leukemia, Division of Cancer Medicine at the University of Texas MD Anderson Cancer Center, discusses how potential doublet…
Rebecca L. Olin, MD, MSCE, associate professor in the Department of Medicine at the University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, discusses changes in…
Jorge Cortes, MD, director of the Georgia Cancer Center in Augusta, GA, provides a comprehensive look at the current challenges specialists face in providing optimal treatment for patients…
